The CAR-T therapies market is characterized by a healthy pipeline of promising therapies, and is projected to be worth around USD 14 Billion in 2030, claims Roots Analysis

Jordan12

278
views

Giventhe success of approved CAR-T cell therapies, such as KYMRIAH®, YESCARTA®,TECARTUS® and BREYANZI®, this upcoming class of biologics are anticipated tocarve out a significant share of the multi-billion dollar cancer immunotherapymarket

RootsAnalysis has announced theaddition of “CAR-T Cell Therapies Market (3rd Edition) by Target Indications (NHL, MultipleMyeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, FollicularLymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), TargetAntigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and KeyGeographies (North America, Europe, Asia Pacific, Latin America, Middle Eastand North Africa, and Rest of the World) – Industry Trends and GlobalForecasts, 2021-2030” report to its list of offerings.

Given their ability to selectively direct acell mediated immune response against cancer cells and, thereby, offerprolonged periods of disease remission, several CAR-T cell therapies provide a promisingtherapeutic strategy for advanced stage cancers and are expected to achieveblockbuster status. With four approved products and many candidate therapiesunder evaluation for the treatment of multiple disease indications, the CAR-Tcell therapy market is characterized by a healthy and growing pipeline.Further, with lucrative financial support and notable increase in partnerships,the CAR-T-cell therapies market is abuzz with activity.

To order this 795+ pagereport, which features 165+ figures and 270+ tables, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html

KeyMarket Insights

Over755 CAR-T cell therapies are currently approved / under development

Close to 40% of the aforementioned candidatesare in preclinical and discovery stages, while more than 25% are beingevaluated in clinical stages (phase I/II and above). Examples of late-stageclinical candidates include bb2121, CD123/CLL1 CAR-T CD19 CAR-T and LCAR-B38MCAR-T / JNJ-68284528.

Currently, the focus is on developing productcandidates to treat various types of cancers

Over 95% of the products in the developmentpipeline are being evaluated for the treatment of hematological malignancies, including(in decreasing order of number of pipeline products) acute lymphoblasticleukemia, non-Hodgkin's lymphoma, multiple myeloma, and acute myeloid leukemia.Only 2% of current pipeline candidates are being developed for the treatment ofnon-oncological indications.

Extensive efforts are underway to improve CAR constructs

Majorityof the product candidates in the clinical pipeline, including the four approveddrug products, are based on second generation CARs. Further, a number of novel therapies armed withfourth generation CAR constructs, CAR-based products containing humanized scFvand bispecific CARs (CD19+CD20 or CD19+CD22 or CD19+CD30) are being evaluatedworldwide.

China is leading the product developmentefforts related to CAR-T cell therapies, in terms of number of active trialsand supporting hospitals

In the last 10 years, over half of the 410clinical trials evaluating various types of CAR-T cell therapies, wereregistered in China. In addition, owning to a favorable clinicalresearch environment, China is presently considered to be among the leadingregions in the CAR-T cell therapy space, with close to 40 industry players andmore than 100 non-industry players, including hospitals and universities,contributing to this field.

Partnership activity within this domain has grown at a CAGRof 26%, between 2011 and 2020

More than 220 agreements were inked related toCAR-T cell therapies, with the maximum activity being reported in 2018.Majority of partnership deals signed within this domain were R&D agreements(21%), technology licensing (20%) and product development and commercializationagreements (11%).

Over USD 13 billion has been invested by bothprivate and public investors, across more than 205 instances

It is important to mention that, between 2013and 2020, majority of the funding was acquired through venture capital rounds(37%), other equity financing elements (24%), grants (12%) and secondaryofferings (12%).

The market is anticipated to grow at a CAGR of over 28%,during the period 2021-2030

Growthin this domain is anticipated to be primarily driven by encouraging clinicaltrial results and the recent success of the four approved CAR-T cell therapies.North America (primarily the US) and Europe are expected to capture over75% of the market share by 2030, in terms of the sales-based revenues.

To request a sample copy / brochure ofthis report, please visit https://www.rootsanalysis.com/reports/269/request-sample.html

Key Questions Answered

§ Whoare the leading industry and non-industry players in this market?

§ Whatare the prevalent R&D trends in CAR-T cell therapies domain?

§ Whatare the key therapeutic areas for which CAR-T cell therapies are being / havebeen developed?

§ Whatare the challenges faced by stakeholders in this industry?

§ Whichare the key geographies where extensive research on CAR-T cell therapies isbeing conducted?

§ Whoare the key investors in this domain?

§ Whoare the key opinion leaders / experts that can help in driving product developmentefforts in this field?

§ Whatkind of partnership models are commonly adopted by industry stakeholders?

§ Whatkind of contract manufacturing support is available for CAR-T cell therapies?

§ Whatkind of promotional strategies are likely to be adopted for CAR-T celltherapies that are approved / commercialized in future?

§ Whatare the factors that are likely to influence the evolution of this upcomingmarket?

§ How is the currentand future market opportunity likely to be distributed across key marketsegments?

The USD 14 billion (by 2030) financial opportunity within the CAR-T celltherapy market has been analyzed across the following segments:

§ Disease indication

§ Non-Hodgkin lymphoma

§ Multiple myeloma

§ Chronic lymphocyticleukemia

§ Acute lymphoblasticleukemia

§ Follicular lymphoma

§ Mantle cell lymphoma

§ Hepatocellularcarcinoma

§ Colorectal cancer

§ Target antigens

§ CD19

§ BCMA

§ CD19, CD22

§ GPC3

§ EGFR

§ KeyGeographical Regions

North America
Europe
Asia Pacific
Latin America
Middle East and North Africa
Rest of the World

The report features inputs from eminentindustry stakeholders, according to whom CAR-T cell therapies are soon likelyto witness increased adoption given their broad scope of applications invarious advanced stage oncological disorders. The report includes detailedtranscripts of discussions held with the following experts:

§ Tim Oldham (ChiefExecutive Officer, Cell Therapies)

§ Troels Jordansen(Chief Executive Officer, Glycostem Therapeutics)

§ Wei (William) Cao(Co-Founder, Chairman and Chief Executive Officer, Gracell Biotechnologies)

§ Miguel Forte (ChiefOperating Officer, TxCell)

§ Adrian Bot (VicePresident, Scientific Affairs, Kite Pharma)

§ Vincent Brichard(Vice President, Immuno-Oncology, Celyad)

§ Brian Dattilo(Manager of Business Development, Waisman Biomanufacturing)

§ Aino Kalervo(Competitive Intelligence Manager, Strategy & Business Development,Theravectys)

§ Xian-Bao Zhan(Professor of Medicine and Director, Department of Oncology, Changhai Hospital)

§ Enkhtsetseg Purev(Assistant Professor of Medicine, University of Colorado)

The research includes brief profiles, featuringan overview of the company, its financial information (if available), and adescription of its product(s), highlighting type of therapy and currentdevelopment status. Each company profile includes technology portfolio (ifavailable), recent developments related to T-cell immunotherapies andmanufacturing capabilities of the companies.

§ Autolus

§ bluebird bio

§ CARsgen Therapeutics

§ Celgene (A BristolMyers Squibb Company)

§ Cellectis

§ Cellular BiomedicineGroup

§ Innovative CellularTherapeutics

§ IovanceBiotherapeutics

§ Kite Pharma (A GileadSciences Company)

§ Kuur Therapeutics

§ Noile-Immune Biotech

§ Novartis